ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2014
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.Journal of the National Cancer Institute · 2015Pooled it
- TNFRSF13B is a potential contributor to prostate cancer.Cancer cell international · 2022Article
- A new method for constructing tumor specific gene co-expression networks based on samples with tumor purity heterogeneity.Bioinformatics (Oxford, England) · 2018Article
- CTD-2020K17.1, a Novel Long Non-Coding RNA, Promotes Migration, Invasion, and Proliferation of Serous Ovarian Cancer Cells In Vitro.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Microbial infection, inflammation and epithelial ovarian cancer.Oncology letters · 2017Article
- Article
- Discover the molecular biomarker associated with cell death and extracellular matrix module in ovarian cancer.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
94 authors at 20 institutions in 10 countries.
Matthew S BlockAuthors' Affiliations: Departments of Medical Oncology.
Bridget CharbonneauHealth Sciences Research, Division of Epidemiology;
Robert A VierkantHealth Sciences Research, Division of Biomedical Statistics and Informatics;
Zachary FogartyHealth Sciences Research, Division of Biomedical Statistics and Informatics;
William R BamletHealth Sciences Research, Division of Biomedical Statistics and Informatics;
Paul D P PharoahOncology and Public Health and Primary Care, University of Cambridge, Cambridge;
Georgia Chenevix-Trench
for AOCS
/ACS Group
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center; Department of Epidemiology, University of Washington, Seattle, Washington;
Daniel CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts;
Celeste Leigh PearceDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center;
Joellen SchildkrautCancer Prevention, Detection, and Control Research Program, Duke Cancer Institute; Department of Community and Family Medicine;
Usha MenonGynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London;
Susanne K KjaerThe Juliane Marie Centre, Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark; Virus, Lifestyle and Genes, Danish Cancer Society Research Center;
Douglas A LevineGynecology Service, Department of Surgery;
Jacek GronwaldDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin; Departments of.
Hoda Anton CulverDepartment of Epidemiology, Center for Cancer Genetics Research and Prevention, School of Medicine, University of California Irvine, Irvine;
Alice S WhittemoreDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Palo Alto;
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute;
Diether LambrechtsVesalius Research Center, VIB; Laboratory for Translational Genetics, Department of Oncology, University of Leuven;
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland;
Jolanta KupryjanczykPathology and.
Jenny Chang-ClaudeGerman Cancer Research Center, Division of Cancer Epidemiology, Heidelberg;
Elisa V BanderaThe Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick;
Estrid HogdallVirus, Lifestyle and Genes, Danish Cancer Society Research Center; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark;
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen; and.
Stanley B KayeDivision of Clinical Studies, The Institute of Cancer Research and the Royal Marsden Hospital;
Peter A FaschingDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center, Erlangen;
Ian CampbellResearch Division, Peter MacCallum Cancer Centre, Melbourne; Department of Pathology, University of Melbourne, Parkville, Victoria;
Marc T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California;
Tanja PejovicDepartment of Obstetrics and Gynecology; Knight Cancer Institute, Oregon Health and Science University;
Yukie T BeanDepartment of Obstetrics and Gynecology; Knight Cancer Institute, Oregon Health and Science University;
Laura E HaysDepartment of Hematology and Oncology and the Knight Cancer Institute, Portland, Oregon;
Galina LurieCancer Epidemiology Program, University of Hawaii Cancer Center, Hawaii;
Diana EcclesFaculty of Medicine, University of Southampton, University Hospital Southampton;
Alexander HeinUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center, Erlangen;
Matthias W BeckmannUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center, Erlangen;
Arif B EkiciInstitute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
James PaulThe Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;
Robert BrownDepartment of Surgery and Cancer, Imperial College London;
James M FlanaganDepartment of Surgery and Cancer, Imperial College London;
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen; and.
Andreas du BoisDepartment of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen; and.
Ira SchwaabInstitut für Humangenetik Wiesbaden, Wiesbaden;
Claus K HogdallThe Juliane Marie Centre, Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark;
Lene LundvallThe Juliane Marie Centre, Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, Denmark;
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York;
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York;
Lisa E PaddockNew Jersey Department of Health, Trenton, New Jersey;
Anja RudolphGerman Cancer Research Center, Division of Cancer Epidemiology, Heidelberg;
Ursula EilberGerman Cancer Research Center, Division of Cancer Epidemiology, Heidelberg;
Agnieszka Dansonka-MieszkowskaPathology and.
Iwona K RzepeckaPathology and.
Izabela Ziolkowska-SetaGynecologic Oncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw;
Louise A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland;
Hannah YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland;
Montserrat Garcia-ClosasBreakthrough Breast Cancer Research Centre, London; Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton;
Evelyn DespierreDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;
Sandrina LambrechtsDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;
Ignace VergoteDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium;
Christine S WalshWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute;
Jenny LesterWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute;
Weiva SiehDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Palo Alto;
Valerie McGuireDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Palo Alto;
Joseph H RothsteinDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Palo Alto;
Argyrios ZiogasDepartment of Epidemiology, Center for Cancer Genetics Research and Prevention, School of Medicine, University of California Irvine, Irvine;
Jan LubińskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin; Departments of.
Cezary CybulskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin; Departments of.
Janusz MenkiszakClinic of Gynaecological Surgery and Oncology, Pomeranian Medical University, Szczecin, Poland;
Allan JensenVirus, Lifestyle and Genes, Danish Cancer Society Research Center;
Simon A GaytherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center;
Susan J RamusDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center;
Aleksandra Gentry-MaharajGynaecological Cancer Research Centre, Women's Cancer, Institute for Women's Health, University College London;
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina;
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center;
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York;
David Van Den BergDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center;
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts;
Allison F VitonisObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School;
Starr M RamirezHealth Sciences Research, Division of Epidemiology;
David N RiderHealth Sciences Research, Division of Biomedical Statistics and Informatics;
Keith L KnutsonImmunology; and.
Thomas A SellersDepartment of Cancer Epidemiology, Division of Population Sciences, Moffitt Cancer Center, Tampa, Florida;
Catherine M PhelanDepartment of Cancer Epidemiology, Division of Population Sciences, Moffitt Cancer Center, Tampa, Florida;
Jennifer A DohertySection of Biostatistics and Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire;
Sharon E JohnattyCancer Division, Queensland Institute of Medical Research, Herston, QLD;
Anna deFazioDepartment of Gynaecological Oncology, Westmead Hospital and Westmead Institute for Cancer Research, University of Sydney at the Westmead Millennium Institute, Westmead, Australia;
Honglin SongOncology and.
Jonathan TyrerOncology and.
Kimberly R KalliAuthors' Affiliations: Departments of Medical Oncology.
Brooke L FridleyDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas; Departments of.
Julie M CunninghamLaboratory Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, Minnesota;
Ellen L GoodeHealth Sciences Research, Division of Epidemiology; egoode@mayo.edu.
University of Southern California · USSamueli Institute · USNational Cancer Institute · USBrigham and Women's Hospital · USGerman Cancer Research Center · DEMemorial Sloan Kettering Cancer Center · USUniversity of California, Irvine · USCancer Institute (WIA) · INHelios Dr. Horst Schmidt Kliniken Wiesbaden · DEBeatson West of Scotland Cancer Centre · GBCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZACedars-Sinai Medical Center · USDartmouth College · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEInstitute of Cancer Research · GBInternational Hereditary Cancer Center · PLMayo Clinic · USMoffitt Cancer Center · USNew Jersey Department of Health · USOregon Health & Science University · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6MHormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5MTRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5MMentoring CoreP20GM103418 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Douglas E Wright · 2012 to 2026
$63.0MTransgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MRisk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3MNorthern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4MUSC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAIMAN, CHRISTOPHER ALAN · 1985 to 2009
$18.2MCancer Research UK 10124Cancer Research UK 13086Cancer Research UK 16561Cancer Research UK A10124Cancer Research UK C12292/A11174Cancer Research UK C1287/A10118Cancer Research UK C1287/A 10710Cancer Research UK C1312/A15589Cancer Research UK C490/A10119Cancer Research UK C490/A10124Cancer Research UK C490/A6187Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384Cancer Research UK C536/A13086Cancer Research UK C536/A6689CIHR MOP-86727NCI NIH HHS CA054419NCI NIH HHS CA106414NCI NIH HHS CA115195NCI NIH HHS K07 CA092044NCI NIH HHS K07 CA095666NCI NIH HHS K07-CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K07-CA143047NCI NIH HHS K22 CA138563NCI NIH HHS K22-CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01-CN55424NCI NIH HHS N01 PC035137NCI NIH HHS N01-PC035137NCI NIH HHS N01 PC067010NCI NIH HHS N01-PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P01-CA017054NCI NIH HHS P01-CA087696NCI NIH HHS P01-CA15083NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA072720NCI NIH HHS P30-CA072720NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA168524NCI NIH HHS P30-CA168524NCI NIH HHS P50 CA105009NCI NIH HHS P50-CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50-CA136393NCI NIH HHS R01-CA014089NCI NIH HHS R01-CA016056NCI NIH HHS R01-CA017054NCI NIH HHS R01 CA049449NCI NIH HHS R01-CA049449NCI NIH HHS R01 CA050385NCI NIH HHS R01-CA050385NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01-CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01-CA058860NCI NIH HHS R01-CA061107NCI NIH HHS R01-CA061132NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA064277NCI NIH HHS R01-CA064277NCI NIH HHS R01 CA067262NCI NIH HHS R01-CA067262NCI NIH HHS R01-CA071766NCI NIH HHS R01 CA074850NCI NIH HHS R01-CA074850NCI NIH HHS R01 CA076016NCI NIH HHS R01-CA076016NCI NIH HHS R01 CA080742NCI NIH HHS R01-CA080742NCI NIH HHS R01-CA080978NCI NIH HHS R01 CA083918NCI NIH HHS R01-CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01-CA087538NCI NIH HHS R01 CA087696NCI NIH HHS R01-CA092044NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA112523NCI NIH HHS R01-CA112523NCI NIH HHS R01 CA114343NCI NIH HHS R01-CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01-CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01-CA126841NCI NIH HHS R01 CA128978NCI NIH HHS R01-CA128978NCI NIH HHS R01 CA136924NCI NIH HHS R01-CA136924NCI NIH HHS R01 CA149429NCI NIH HHS R01-CA149429NCI NIH HHS R01-CA61107NCI NIH HHS R03 CA113148NCI NIH HHS R03-CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R25 CA092049NCI NIH HHS R37 CA070867NCI NIH HHS R37-CA070867NCI NIH HHS R37-CA70867NCI NIH HHS U01 CA069417NCI NIH HHS U01-CA069417NCI NIH HHS U01-CA071966NCI NIH HHS U19 CA148112NCI NIH HHS U19-CA148112NCI NIH HHS U19 CA148537NCI NIH HHS U19-CA148537NIGMS NIH HHS P20 GM103418NIGMS NIH HHS P20-GM103418NIGMS NIH HHS R21 GM086689NIGMS NIH HHS R21-GM86689
Abstract
Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the key genetic determinants of inflammation and immunity that affect prognosis are not known. The nuclear factor-κB (NF-κB) transcription factor family plays an important role in many immune and inflammatory responses, including the response to cancer. We studied common inherited variation in 210 genes in the NF-κB family in 10,084 patients with invasive EOC (5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian Cancer Association Consortium. Associations between genotype and overall survival were assessed using Cox regression for all patients and by major histology, adjusting for known prognostic factors and correcting for multiple testing (threshold for statistical significance, P < 2.5 × 10(-5)). Results were statistically significant when assessed for patients of a single histology. Key associations were with caspase recruitment domain family, member 11 (CARD11) rs41324349 in patients with mucinous EOC [HR, 1.82; 95% confidence interval (CI), 1.41-2.35; P = 4.13 × 10(-6)] and tumor necrosis factor receptor superfamily, member 13B (TNFRSF13B) rs7501462 in patients with endometrioid EOC (HR, 0.68; 95% CI, 0.56-0.82; P = 2.33 × 10(-5)). Other associations of note included TNF receptor-associated factor 2 (TRAF2) rs17250239 in patients with high-grade serous EOC (HR, 0.84; 95% CI, 0.77-0.92; P = 6.49 × 10(-5)) and phospholipase C, gamma 1 (PLCG1) rs11696662 in patients with clear cell EOC (HR, 0.43; 95% CI, 0.26-0.73; P = 4.56 × 10(-4)). These associations highlight the potential importance of genes associated with host inflammation and immunity in modulating clinical outcomes in distinct EOC histologies.
Indexed as
AdultAgedCarcinoma, Ovarian EpithelialFemaleGenotypeHumansMiddle AgedNeoplasm InvasivenessNeoplasms, Glandular and EpithelialNF-kappa BOvarian NeoplasmsPolymorphism, Single NucleotideProportional Hazards ModelsSignal TransductionNF-kappa B
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.